Submitted additional EB-101 transport stability data to FDA in response to Clinical Hold Letter; CMC clearance for pivotal VIITALTM Phase 3 trial anticipated in Q4 2019 Publication...
Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Industrials, Technology and Basic Materials sectors led shares lower. At the close in NYSE, the...
As expected, the European Commission approves Ultragenyx's Mepsevii (vestronidase alfa) for the treatment of non-neurological manifestations of mucopolysaccharidosis VII (MPS VII)...
Abeona Therapeutics Inc (NASDAQ:ABEO) has been in a downtrend since 9.00, and change, down to 1.46, not even three weeks ago. It exploded two weeks ago, and has been coiling and...
Investors in Abeona Therapeutics Inc. (NASDAQ:ABEO) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2019 $2.50...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Sell|
|Technical Indicators||Strong Sell||Sell||Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Engulfing Bearish||30||1||Nov 15, 2019 03:00PM|
|Homing Pigeon||15||1||Nov 15, 2019 03:30PM|
|Engulfing Bearish||1M||6||May 19|
|Cypress Energy Partners LP||9.67||9.86||9.59||+0.28||+2.98%||20.50K||15/11|
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.